Browse existing research summaries on rapamycin and longevity science.
A whole-organism single-nucleus atlas of rapamycin-treated fruit flies (505,731 nuclei, 181 cell types) identifies a rapamycin-sensitive convergent aging state marked by Fkbp12 and mTORC1-linked metabolism that is reduced more strongly in females, matching their larger lifespan extension.
Design and rationale for a randomised, placebo-controlled rapamycin trial in healthy middle-aged companion dogs — the first rigorous lifespan-and-healthspan test of a pharmacological ageing intervention in dogs.
In amyloid-overexpressing mice carrying human APOE4, 16 weeks of rapamycin restored blood-brain barrier amyloid clearance, cerebral blood flow and neurotransmitter levels before symptoms appeared, with partly different effects in APOE3 mice.
In rats doing a resistance-exercise model, rapamycin fully blocked exercise-induced ribosome biogenesis but only partly reduced muscle protein synthesis and the muscle growth produced by four weeks of training.
Nine weeks of daily rapamycin in adult mice reduced proliferating neural progenitors in both neurogenic niches and lowered markers of new neurons, whereas metformin given at a dose that also inhibited mTOR in the brain had no such effect.
